RCUS vs NTLA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NTLA Captures Institutional Edge (2โ1 Pillars ยท 5โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Intellia Therapeutics, Inc (NTLA) driven by superior Growth & Margin, Momentum & Technical while RCUS counters with relative strength in Options & Structure. Fundamentally, RCUS trades at N/M Forward P/E with -475.0% operating margin (-65.4% YoY revenue) versus NTLA at N/M Forward P/E and -826.0% operating margin (-48.0% YoY). In options structure, RCUS sits in BREAKDOWN (1st %ile IV; Dealer Gamma Walls on Pro) against NTLA sits in BREAKDOWN (78th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | RCUS Revenue | NTLA Revenue | RCUS Op. Margin | NTLA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $10M | $30M | -656.8% | -298.6% | NTLA |
| FY2019 | $10M | $40M | -591.4% | -246.8% | NTLA |
| FY2020 | $80M | $60M | -159.0% | -235.5% | RCUS |
| FY2021 | $380M | $30M | 14.1% | -810.4% | RCUS |
| FY2022 | $40M | $50M | -736.8% | -879.0% | RCUS |
| FY2023 | $40M | $40M | -918.9% | -1420.5% | RCUS |
| FY2024 | $50M | $60M | -647.1% | -923.1% | RCUS |
| FY2025 | $30M | $70M | -1169.7% | -651.7% | NTLA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RCUS | NTLA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.6B | $1.5B | Larger Scale | RCUS |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -65.4% | -48.0% | Higher Growth | NTLA |
| Operating Margin (TTM) Profitability | -475.0% | -826.0% | Higher Margin | RCUS |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -114.1% | -62.6% | Higher ROE | NTLA |
| 52-Week Range Position Momentum | 1% ($17โ$32) | 20% ($8โ$18) | Stronger Trend | NTLA |
| Beta / 30D Volatility Risk Regime | 1.56ฮฒ ยท 90% Vol | 2.30ฮฒ ยท 87% Vol | Lower Realized Risk | NTLA |
| Unified Institutional Score Composite Signal | 48.4 / 100 (HOLD) | 50.7 / 100 (HOLD) | Higher Composite | NTLA |